Celldex Therapeutics Inc
CLDX26.400USD
-0.430-1.60%
Cierre 12/26, 16:00（ET）Cotizaciones retrasadas 15 min
1.75BCap. mercado
PérdidaP/E TTM
Más Datos de Celldex Therapeutics Inc Compañía
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Información de Celldex Therapeutics Inc
Símbolo de cotizaciónCLDX
Nombre de la empresaCelldex Therapeutics Inc
Fecha de salida a bolsaMay 15, 1986
Director ejecutivoMarucci (Anthony S)
Número de empleados186
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 15
Dirección53 Frontage Road
CiudadHAMPTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal08827
Teléfono19084547120
Sitio Webhttps://celldex.com/
Símbolo de cotizaciónCLDX
Fecha de salida a bolsaMay 15, 1986
Director ejecutivoMarucci (Anthony S)
Ejecutivos de Celldex Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Anthony S. Marucci
Mr. Anthony S. Marucci
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.64K
+1.48%
Mr. Freddy A. Jimenez, Esq., J.D.
Mr. Freddy A. Jimenez, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
29.20K
-12.49%
Dr. Diane C. Young, M.D.
Dr. Diane C. Young, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
17.11K
-63.67%
Dr. Margo Heath-Chiozzi, M.D.
Dr. Margo Heath-Chiozzi, M.D.
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
13.74K
+2.70%
Ms. Elizabeth Crowley
Ms. Elizabeth Crowley
Senior Vice President, Chief Product Development Officer
Senior Vice President, Chief Product Development Officer
9.07K
--
Dr. Tibor Keler, Ph.D.
Dr. Tibor Keler, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
7.36K
--
Mr. Herbert J. (Herb) Conrad
Mr. Herbert J. (Herb) Conrad
Independent Director
Independent Director
2.56K
--
Mr. James J. (Jim) Marino
Mr. James J. (Jim) Marino
Independent Director
Independent Director
2.20K
--
Mr. Keith L. Brownlie, CPA
Mr. Keith L. Brownlie, CPA
Independent Director
Independent Director
666.00
--
Ms. Teri L. Lawver
Ms. Teri L. Lawver
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Anthony S. Marucci
Mr. Anthony S. Marucci
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.64K
+1.48%
Mr. Freddy A. Jimenez, Esq., J.D.
Mr. Freddy A. Jimenez, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
29.20K
-12.49%
Dr. Diane C. Young, M.D.
Dr. Diane C. Young, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
17.11K
-63.67%
Dr. Margo Heath-Chiozzi, M.D.
Dr. Margo Heath-Chiozzi, M.D.
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
13.74K
+2.70%
Ms. Elizabeth Crowley
Ms. Elizabeth Crowley
Senior Vice President, Chief Product Development Officer
Senior Vice President, Chief Product Development Officer
9.07K
--
Dr. Tibor Keler, Ph.D.
Dr. Tibor Keler, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
7.36K
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Wellington Management Company, LLP
11.13%
Kynam Capital Management LP
9.18%
BlackRock Institutional Trust Company, N.A.
6.85%
The Vanguard Group, Inc.
5.93%
Point72 Asset Management, L.P.
5.86%
Otro
61.05%
Accionistas
Accionistas
Proporción
Wellington Management Company, LLP
11.13%
Kynam Capital Management LP
9.18%
BlackRock Institutional Trust Company, N.A.
6.85%
The Vanguard Group, Inc.
5.93%
Point72 Asset Management, L.P.
5.86%
Otro
61.05%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
40.48%
Hedge Fund
32.83%
Investment Advisor/Hedge Fund
31.61%
Venture Capital
2.69%
Research Firm
2.39%
Bank and Trust
0.38%
Pension Fund
0.32%
Individual Investor
0.30%
Insurance Company
0.04%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
423
73.56M
131.89%
+1.59M
2025Q3
430
71.99M
131.15%
-2.21M
2025Q2
424
73.79M
132.42%
-1.31M
2025Q1
421
75.04M
133.66%
-13.71M
2024Q4
421
74.73M
125.30%
+1.68M
2024Q3
414
73.10M
121.03%
+1.84M
2024Q2
417
71.21M
123.61%
+212.73K
2024Q1
405
71.18M
106.49%
+1.00M
2023Q4
395
62.54M
112.65%
+8.43M
2023Q3
391
51.91M
128.09%
+289.51K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Wellington Management Company, LLP
5.23M
7.88%
-3.12M
-37.37%
Jun 30, 2025
Kynam Capital Management LP
6.10M
9.19%
-399.27K
-6.14%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.59M
6.91%
-38.52K
-0.83%
Jun 30, 2025
The Vanguard Group, Inc.
3.94M
5.94%
+56.45K
+1.45%
Jun 30, 2025
Point72 Asset Management, L.P.
2.80M
4.22%
+180.55K
+6.89%
Jun 30, 2025
Bellevue Asset Management AG
3.31M
4.98%
+235.95K
+7.68%
Jun 30, 2025
Fidelity Management & Research Company LLC
3.95M
5.95%
+62.97K
+1.62%
Jun 30, 2025
Commodore Capital LP
3.45M
5.2%
+100.00K
+2.99%
Jun 30, 2025
State Street Investment Management (US)
2.41M
3.62%
-400.86K
-14.28%
Jun 30, 2025
T. Rowe Price Associates, Inc.
3.75M
5.65%
+398.14K
+11.88%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Simplify Propel Opportunities ETF
3.36%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
ALPS Medical Breakthroughs ETF
0.74%
State Street SPDR S&P Biotech ETF
0.64%
Direxion Daily S&P Biotech Bull 3X Shares
0.39%
Avantis US Small Cap Equity ETF
0.16%
First Trust Small Cap Growth AlphaDEX Fund
0.15%
Nuveen ESG Small-Cap ETF
0.14%
T Rowe Price Small-Mid Cap ETF
0.13%
Fidelity Fundamental Small-Mid Cap ETF
0.13%
Ver más
Simplify Propel Opportunities ETF
Proporción3.36%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.89%
ALPS Medical Breakthroughs ETF
Proporción0.74%
State Street SPDR S&P Biotech ETF
Proporción0.64%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.39%
Avantis US Small Cap Equity ETF
Proporción0.16%
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.15%
Nuveen ESG Small-Cap ETF
Proporción0.14%
T Rowe Price Small-Mid Cap ETF
Proporción0.13%
Fidelity Fundamental Small-Mid Cap ETF
Proporción0.13%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Celldex Therapeutics Inc?
Los cinco principales accionistas de Celldex Therapeutics Inc son:
Wellington Management Company, LLP posee 5.23M acciones, lo que representa el 7.88% del total de acciones.
Kynam Capital Management LP posee 6.10M acciones, lo que representa el 9.19% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 4.59M acciones, lo que representa el 6.91% del total de acciones.
The Vanguard Group, Inc. posee 3.94M acciones, lo que representa el 5.94% del total de acciones.
Point72 Asset Management, L.P. posee 2.80M acciones, lo que representa el 4.22% del total de acciones.
Wellington Management Company, LLP posee 5.23M acciones, lo que representa el 7.88% del total de acciones.
Kynam Capital Management LP posee 6.10M acciones, lo que representa el 9.19% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 4.59M acciones, lo que representa el 6.91% del total de acciones.
The Vanguard Group, Inc. posee 3.94M acciones, lo que representa el 5.94% del total de acciones.
Point72 Asset Management, L.P. posee 2.80M acciones, lo que representa el 4.22% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Celldex Therapeutics Inc?
Los tres principales tipos de accionista de Celldex Therapeutics Inc son:
Wellington Management Company, LLP
Kynam Capital Management LP
BlackRock Institutional Trust Company, N.A.
Wellington Management Company, LLP
Kynam Capital Management LP
BlackRock Institutional Trust Company, N.A.
¿Cuántas instituciones poseen acciones de Celldex Therapeutics Inc (CLDX)?
A fecha de 2025Q4, 423 instituciones poseen acciones de Celldex Therapeutics Inc, con un valor de mercado combinado de aproximadamente 73.56M, lo que representa el 131.89% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en 0.74%.
¿Cuál es la mayor fuente de ganancias de Celldex Therapeutics Inc?
El --, el segmento empresarial -- generó la ganancia más alta para Celldex Therapeutics Inc, ascendiendo a -- y representando el --% de la ganancia total.
